Basel, Switzerland-based biotech company Therachon has appointed Dr Maarten Kraan as its new chief medical officer in a role that will see him focus on the clinical development of TA-46 – Therachon’s leading drug in development for achondroplasia.
Kraan has held numerous roles such as vice president, immunosciences at Bristol-Myers Squibb, vice president, head of clinical research and experimental development at Roche, and most recently as head of innovative medicines respiratory and inflammation at AstraZeneca.
Luca Santarelli, chief medical officer at Therachon, said: “Dr Kraan’s wealth of translational and drug development expertise is critical during this exciting time in our company’s growth. He will play a key role in guiding TA-46 from discovery into clinical development and helping us fulfill our mission of developing medicines for rare, genetic diseases.”
In addition to his new role Dr Kraan will continue to serve as an adjunct professor at Goteborg University in Sweden.